Abbott Laboratories (ABT)

48.91
NYSE : Health Care
Prev Close 48.91
Day Low/High 0.00 / 0.00
52 Wk Low/High 36.76 / 49.59
Avg Volume 6.80M
Exchange NYSE
Shares Outstanding 1.74B
Market Cap 85.17B
EPS 0.90
P/E Ratio 55.15
Div & Yield 1.06 (2.20%)

Latest News

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

Jim Cramer discusses bonds and also talks about why panicking off the Fed is a superbad idea.

Weekly Roundup

Tech rotation, oil and Fed rate hike keep markets on even (make that flat) keel. Several portfolio positions get beefed up.

Cramer: You Can't Bet Against the Bonds

Cramer: You Can't Bet Against the Bonds

A rotation that started as the minor chord of the rotational symphony and is now the major one.

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

Abbott Is on Track to Meet Integration Objectives

In turn, this will increase the company's profit margins.

How We are Positioning on This Rotation

As investors book profits in tech names, we want to let the sellers tire themselves out before making a big move.

Abbott Laboratories Saw a Recent Breakout

Abbott Laboratories Saw a Recent Breakout

Barring a close below $46, we are likely to see ABT remain firm and work higher.

Last Week's Portfolio Updates

We exited HP Enterprise and brought Abbott Labs in from the Bullpen.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Weekly Roundup

After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.

Tech Suffers Rotation Devastation

We pretty much saw this coming.

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol-Myers will conduct the study and both companies will evaluate the findings.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Exiting This Tech Name

We are exiting HPE to build cash and make room for another potential name.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CIO, FLO, TGP Downgrades: ABT, ADSK, AEG, DISCA, GPS, GSM, KEYS, NVFY Initiations: BATRA, BATRK Read on to get TheStreet Quant Ratings' detailed report:

Goldman Starts Abbott Laboratories at 'Neutral'

Goldman Starts Abbott Laboratories at 'Neutral'

Analysts also gave the company a $45 price target

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

Abbott Announces CE Mark For TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

New Cardiac Ablation Catheter Integrates with 3D Mapping System to Advance the Treatment of Atrial Fibrillation

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Abbott Announces CE Mark And First Use Of The World's First Smartphone Compatible Insertable Cardiac Monitor

THE NEW CONFIRM RX™ ICM AUTOMATICALLY CAPTURES VITAL CARDIAC INFORMATION AND RELAYS DATA TO PHYSICIANS VIA THE MYMERLIN™ MOBILE APP ENABLING REMOTE MONITORING OF IRREGULAR HEART RHYTHMS

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.